SGMT Key Statistics, Chart & Performance
The current stock price of SGMT is 6.19 USD. In the past month the price decreased by -17.69%. In the past year, price increased by 41%.
SGMT Latest News, Press Relases and Analysis
SGMT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.61 | 394.34B | ||
| AMGN | AMGEN INC | 14.69 | 172.98B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.46 | 112.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.62 | 73.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 843.18 | 56.81B | ||
| INSM | INSMED INC | N/A | 41.92B | ||
| NTRA | NATERA INC | N/A | 33.00B | ||
| BIIB | BIOGEN INC | 10.78 | 26.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.17 | 20.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.16B | ||
| INCY | INCYTE CORP | 15.06 | 18.98B |
Related stock screener links
About SGMT
Company Profile
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in San Mateo, California and currently employs 14 full-time employees. The company went IPO on 2023-07-14. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The firm is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
Company Info
SAGIMET BIOSCIENCES INC-A
155 Bovet Rd., Suite 303
San Mateo CALIFORNIA US
Employees: 14
Phone: 16505618600
SAGIMET BIOSCIENCES INC-A / SGMT FAQ
What does SAGIMET BIOSCIENCES INC-A do?
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in San Mateo, California and currently employs 14 full-time employees. The company went IPO on 2023-07-14. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The firm is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
What is the current price of SGMT stock?
The current stock price of SGMT is 6.19 USD. The price decreased by -3.13% in the last trading session.
What is the dividend status of SAGIMET BIOSCIENCES INC-A?
SGMT does not pay a dividend.
What is the ChartMill rating of SAGIMET BIOSCIENCES INC-A stock?
SGMT has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for SAGIMET BIOSCIENCES INC-A?
SAGIMET BIOSCIENCES INC-A (SGMT) operates in the Health Care sector and the Biotechnology industry.
Should I buy SGMT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SGMT.
What is the outstanding short interest for SAGIMET BIOSCIENCES INC-A?
The outstanding short interest for SAGIMET BIOSCIENCES INC-A (SGMT) is 11.04% of its float.
SGMT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SGMT. When comparing the yearly performance of all stocks, SGMT is one of the better performing stocks in the market, outperforming 82.35% of all stocks.
SGMT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SGMT. SGMT has a great financial health rating, but its profitability evaluates not so good.
SGMT Financial Highlights
Over the last trailing twelve months SGMT reported a non-GAAP Earnings per Share(EPS) of -1.78. The EPS decreased by -4.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.91% | ||
| ROE | -48.36% | ||
| Debt/Equity | 0 |
SGMT Forecast & Estimates
16 analysts have analysed SGMT and the average price target is 26.86 USD. This implies a price increase of 333.93% is expected in the next year compared to the current price of 6.19.